title: mGluR1, but not mGluR5, activates feed-forward inhibition in the medial prefrontal cortex to impair decision making.
abstract: Cognitive flexibility depends on the integrity of the prefrontal cortex (PFC). We showed previously that impaired decision making in pain results from amygdala-driven inhibition of medial PFC neurons, but the underlying mechanisms remain to be determined. Using whole cell patch clamp in rat brain slices and a cognitive behavioral task, we tested the hypothesis that group I metabotropic glutamate receptors (mGluRs) activate feed-forward inhibition to decrease excitability and output function of PFC pyramidal cells, thus impairing decision making. Polysynaptic inhibitory postsynaptic currents (IPSCs) and monosynaptic excitatory postsynaptic currents (EPSCs) were evoked in layer V pyramidal cells by stimulating presumed amygdala afferents. An mGluR1/5 agonist [(S)-3,5-dihydroxyphenylglycine, DHPG] increased synaptic inhibition more strongly than excitatory transmission. The facilitatory effects were blocked by an mGluR1 [(S)-(+)-α-amino-4-carboxy-2-methylbenzeneacetic acid, LY367385], but not mGluR5, antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine. IPSCs were blocked by bicuculline and decreased by 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt (NBQX). Facilitation of synaptic inhibition by DHPG was glutamate driven because it was blocked by NBQX. DHPG increased frequency but not amplitude of spontaneous IPSCs; consistent with action potential-dependent synaptic inhibition, tetrodotoxin (TTX) prevented the facilitatory effects. DHPG decreased synaptically evoked spikes (E-S coupling) and depolarization-induced spiking [frequency-current (f-I) relationship]. This effect was indirect, resulting from glutamate-driven synaptic inhibition, because it persisted when a G protein blocker was included in the pipette but was blocked by GABA(A) receptor antagonists and NBQX. In contrast, DHPG increased E-S coupling and f-I relationships in mPFC interneurons through a presynaptic action, further supporting the concept of feed-forward inhibition. DHPG also impaired the ability of the animals to switch strategies in a decision-making task; bicuculline restored normal decision making, whereas a GABA(A) receptor agonist (muscimol) mimicked the decision-making deficit. The results show that mGluR1 activates feed-forward inhibition of PFC pyramidal cells to impair cognitive functions.
authors: Department of Neuroscience and Cell Biology, The University of Texas Medical Branch, Galveston, TX 77555-1069, USA.
authors: Hao
authors: H
authors: Sun
authors: Volker
authors: V
authors: Neugebauer
references: J Neurosci. 2007 Oct 24;27(43):11496-500
references: 17959792
references: Annu Rev Neurosci. 2004;27:1-28
references: 15217324
references: Neuroscience. 2006;139(3):1039-48
references: 16527423
references: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):18004-9
references: 19815518
references: Annu Rev Pharmacol Toxicol. 2010;50:295-322
references: 20055706
references: J Neurosci. 2006 Jun 14;26(24):6458-68
references: 16775133
references: Nat Rev Neurosci. 2004 Oct;5(10):793-807
references: 15378039
references: Eur J Pharmacol. 2010 Aug 10;639(1-3):2-16
references: 20371230
references: Neuropsychopharmacology. 2008 Jan;33(1):141-65
references: 17805309
references: Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2423-8
references: 19171885
references: J Neurosci. 2003 Jan 1;23(1):52-63
references: 12514201
references: J Neurosci Methods. 2006 Mar 15;151(2):148-58
references: 16154203
references: Nat Neurosci. 2009 Jul;12(7):939-45
references: 19503087
references: J Neurophysiol. 1995 Dec;74(6):2329-35
references: 8747195
references: Trends Neurosci. 2008 May;31(5):234-42
references: 18395805
references: Respir Physiol Neurobiol. 2008 Dec 31;164(3):394-400
references: 18824146
references: J Neurosci. 2008 Apr 9;28(15):3861-76
references: 18400885
references: Nat Neurosci. 2007 Apr;10(4):462-8
references: 17334362
references: Neuropharmacology. 2009;56 Suppl 1:63-72
references: 18692512
references: Neuron. 2007 Apr 5;54(1):51-8
references: 17408577
references: Eur J Pharmacol. 2010 Aug 10;639(1-3):33-9
references: 20371231
references: Brain Res Bull. 2005 Feb 15;65(1):11-6
references: 15680540
references: Proc Natl Acad Sci U S A. 2000 May 23;97(11):6144-9
references: 10823957
references: J Neurophysiol. 2004 Jan;91(1):13-24
references: 13679408
references: Brain Res. 1996 May 13;720(1-2):211-9
references: 8782914
references: J Neurophysiol. 1997 Nov;78(5):2287-95
references: 9356382
references: J Neurosci. 2010 Apr 14;30(15):5451-64
references: 20392966
references: Curr Opin Neurobiol. 2004 Apr;14(2):148-55
references: 15082318
references: Science. 2004 May 7;304(5672):878-80
references: 15131308
references: J Neurophysiol. 1998 Aug;80(2):621-7
references: 9705455
references: Neuroscience. 2006 Sep 29;142(1):1-20
references: 16887277
references: J Neurosci. 2004 Nov 17;24(46):10410-5
references: 15548656
references: J Neurosci. 2011 Jan 19;31(3):1114-27
references: 21248136
references: J Comp Neurol. 2003 Dec 22;467(4):521-35
references: 14624486
references: Biol Psychiatry. 2002 Oct 1;52(7):708-15
references: 12372661
references: J Pharmacol Exp Ther. 2005 Jul;314(1):139-47
references: 15769865
references: Neurosci Lett. 2008 Sep 19;442(3):239-43
references: 18621097
references: Biol Psychiatry. 2010 Feb 1;67(3):199-207
references: 19833323
references: Neuropsychiatr Dis Treat. 2006 Dec;2(4):531-6
references: 19412501
references: Mol Pain. 2007 Mar 28;3:8
references: 17391515
references: J Neurophysiol. 2010 Jul;104(1):218-29
references: 20463194
references: Neuroscience. 1996 Nov;75(1):123-31
references: 8923528
references: Ann N Y Acad Sci. 2003 Apr;985:356-69
references: 12724171
references: J Neurosci. 1994 Aug;14(8):5120-30
references: 8046472
references: J Neurophysiol. 1996 Aug;76(2):651-67
references: 8871189
references: Nature. 2008 Jul 31;454(7204):600-6
references: 18615015
references: J Comp Neurol. 1990 Aug 1;298(1):40-9
references: 1698828
references: Neuron. 2007 Mar 1;53(5):735-46
references: 17329212
references: Prog Neurobiol. 2009 Feb;87(2):81-97
references: 18952143
references: Nat Rev Neurosci. 2009 Jun;10(6):423-33
references: 19469026
references: Pain. 2004 Mar;108(1-2):129-36
references: 15109516
references: Neuroscience. 2007 Mar 2;145(1):225-31
references: 17204373
references: Eur J Pharmacol. 2010 Aug 10;639(1-3):47-58
references: 20371237
references: J Neurosci. 1999 Jul 1;19(13):5473-81
references: 10377356
references: CNS Drug Rev. 2006 Summer;12(2):149-66
references: 16958988
references: Brain. 2008 Jan;131(Pt 1):155-64
references: 18065438
references: Cereb Cortex. 2006 Apr;16(4):541-52
references: 16033926
references: Science. 2009 Aug 7;325(5941):760-4
references: 19661434
references: Nat Rev Neurosci. 2005 Apr;6(4):312-24
references: 15803162
references: Nat Neurosci. 2007 Aug;10(8):949-51
references: 17603478
references: Nat Rev Neurosci. 2008 Jun;9(6):423-36
references: 18464791
references: Neuropsychopharmacology. 2008 Sep;33(10):2442-55
references: 18059437
references: Nature. 1997 Dec 11;390(6660):607-11
references: 9403689
references: Neuron. 2008 Jun 12;58(5):662-71
references: 18549779
references: J Neurophysiol. 2004 Sep;92(3):1558-65
references: 15152021
references: Neuroscience. 2009 Jul 7;161(3):671-9
references: 19362121
references: Cereb Cortex. 2005 Apr;15(4):409-18
references: 15749985
references: J Neurophysiol. 2001 May;85(5):2213-23
references: 11353036